KOGENATE® Bayer users
Research and development
Patient information
You can download the following files in PDF format :
Summary of Product Characteristics Prescribing Information Patient Information Leaflet
Bayer is continuously making investments in research and development to improve the safety and efficacy of our products while facilitating improvements in the patient's quality of life.
Future research is intended to further enhance the convenience and efficacy of haemophilia treatment by:
- Modifying the FVIII molecule through recombinant technology and formulation to extend half-life
Further information
For any medical information please contact Bayer Medical Information:
Telephone: 01635 563116
Produced by Bayer. This website is intended for residents of the UK.
Date of preparation: December 2010
UK.PH.HN.KOG.2010.250.56.3